NuView Life Sciences is a clinical-stage precision oncology company based in Park City, Utah. The company develops both in vitro and in vivo diagnostics and theranostic programs. NuView plans to complete a 600-patient in vitro double-blind clinical trial as part of the FDA approval process. To fund these efforts it secured a $90 million funding agreement with GEM Global Yield. The agreement provides a 36-month drawdown period and is structured as a firm-commitment common-share purchase contingent on filing a Registration Statement with the U.S. SEC. The company is led by Chairman and CEO Paul Crowe.

Total raised

$90M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2020